Samsung Biologics Expands, Buys U.S. Drug Plant From GSK

Samsung Biologics Co. agreed to buy a U.S. drug production facility from GlaxoSmithKline plc for $280 million, its first manufacturing site on American soil, the companies said in announcements on December 21 and 22, 2025. The transaction gives Samsung ownership of the Human Genome Sciences Inc. manufacturing complex in Rockville, Maryland, which comprises two Current Good Manufacturing Practice plants with a combined drug substance capacity of roughly 60,000 liters.

The purchaser will be Samsung Biologics America Inc., the U.S. wholly owned subsidiary of the South Korean contract development and manufacturing organization. Samsung said it will retain more than 500 employees at the Rockville site to ensure continuity of operations and plans additional investments to upgrade technology and expand capacity to support both clinical and commercial biologics manufacturing. The stated purchase price is subject to adjustment at closing, and the takeover is expected to complete toward the end of the first quarter of 2026.

The acquisition is a strategic response to long term demand in the U.S. market and an effort to deepen Samsung’s North American footprint. Company statements framed the move as bolstering U.S. supply chain resilience and positioning Samsung to offer clients flexible, multi site contract manufacturing options across the U.S. and Korea. Industry observers also noted the transaction could reduce exposure to U.S. trade frictions and align Samsung with national security oriented rules that restrict certain biotechnology services and equipment in federally funded programs.

Market analysts highlighted the importance of local manufacturing for big pharmaceutical customers that insist on multiple suppliers. “Big Pharma favors dual sourcing,” said Wi Hae Joo, an analyst at Korea Investment & Securities Co. in Seoul, describing Samsung’s U.S. footprint as a key event for expanding its order base.

Commercial context for the acquisition includes a separate announcement of $828 million in three orders from European pharmaceutical makers, disclosed alongside the purchase. Samsung has not tied specific orders to the Rockville site, but the company presented the acquisition as a way to strengthen its contract development and manufacturing services for biologics at both clinical and commercial scale. Samsung Biologics is widely identified as one of the world’s largest contract drugmakers, and the Maryland facility will be integrated into its global manufacturing network.

Deal mechanics reported by the companies use both asset acquisition language and references to taking ownership of Human Genome Sciences operations, reflecting an acquisition of the site and its functions rather than a simple real estate purchase. Key items to watch in coming months include formal regulatory filings, any adjustments to the purchase price at closing, the timetable and scope of planned upgrades at Rockville, and how the new site affects Samsung’s overall capacity utilization and order flow.

For U.S. customers and policymakers, the transaction signals growing international investment in domestic biologics capacity at a time when supply chain resilience and national security considerations are reshaping procurement and sourcing decisions across the pharmaceutical industry.